Ph.D.; Director of the Center for Obesity and Metabolic Diseases at Chengdu Third People's Hospital. Chair of the Specialized Committee on Weight Loss and Metabolic Surgery of the Sichuan Medical Communication Association; Vice Chair of the Specialized Committee on Weight Management of the Sichuan International Medical Exchange and Promotion Association; Council Member of the Asia-Pacific Association for Obesity and Sarcopenic Metabolic Disorders (APAOSM); Member of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
Research focuses on obesity and metabolic surgery. Published 10 academic papers, including 7 indexed in the Science Citation Index (SCI); contributed to 3 clinical guidelines and expert consensuses; holds 2 invention patents and co-authored 1 academic book. Principal Investigator of a research project funded by the Sichuan Provincial Health Commission; participated in projects funded by the National Natural Science Foundation of China and a municipal science and technology authority. Honors include the Third Prize of the Sichuan Medical Science and Technology Award (2021) and a Poster Award at the IFSO World Congress (2024).

Hongmei Zhu is an Assistant Researcher and a Master's Supervisor. Her professional and academic appointments include Council Member of the Asia-Pacific Alliance for Obesity and Sarcopenia Metabolism (APAOSM), Standing Committee Member of the Weight Management and Metabolic Surgery Committee of the Sichuan Medical Communication Association, and Committee Member of the Obesity and Metabolic Diseases Branch of the Sichuan Medical Science and Technology Innovation Research Association. She also serves as a Young Editorial Board Member of Metabolism and Target Organ Damage and Food & Medicine Homology.
Her research interests include genomic epidemiology and evidence-based medicine in diabetes, obesity, metabolic diseases, and neurodegenerative diseases, as well as research ethics. She previously served as a Scientific Editor for MedComm (IF = 10.7), an English-language journal edited by Academician Wei Yuquan. At the Shenzhen Institute of Artificial Intelligence and Robotics for Society (AIRS), she was responsible for the international collaborative project between AIRS and Professor David Robertson of the University of Edinburgh, entitled "PHI (Precision Health Informatics) – Phase 1: ALPHA (Automating Living Precision Health Analytics)." She has published more than ten papers as first or corresponding author in leading SCI-indexed journals, including JAMA Network Open, Diabetologia, Obesity Reviews, and International Journal of Surgery. She currently oversees clinical research at the Center for Obesity and Metabolic Diseases, managing one Phase I drug clinical trial, three medical device Good Clinical Practice (GCP) trials, and six investigator-initiated multicenter clinical studies involving drugs or medical devices (IITs), including the ORDER and SMART studies.
Topic: One-year outcomes of sleeve gastrectomy, sleeve gastrectomy with jejunojejunal bypass, and single anastomosis sleeve ileal bypass in Chinese patients with BMI ≥37.5 kg/m²: A propensity score-matched retrospective study

Qiuye Cheng is an Upper Gastrointestinal and Bariatric Surgeon at St George Private Hospital in Sydney, Australia. He is also a Founding Member of the International Obesity Society (IOS).
His clinical practice focuses on metabolic surgery, upper gastrointestinal surgery, and robotic surgery, with particular expertise in complex primary and revisional bariatric procedures. His research and clinical interests include optimizing long-term outcomes following metabolic surgery and advancing the specialty through multidisciplinary collaboration, education, clinical research, and evidence-based surgical practice.
Topic: Gastric sleeve leak management and treatment algorithm depending on severity

B. Ramos-Molina is the Principal Investigator and Head of the Obesity, Diabetes and Metabolism (ODiM) Research Group at the Biomedical Research Institute of Murcia (IMIB), Spain.
His research focuses on the molecular mechanisms underlying obesity-related metabolic disorders, particularly metabolic dysfunction-associated steatotic liver disease (MASLD) and its progression towards metabolic dysfunction-associated steatohepatitis (MASH). His group combines translational research, multi-omics approaches, and advanced human organoid technologies, with a particular focus on developing and characterizing patient-derived liver organoids from individuals with obesity. These models are used to investigate disease mechanisms, identify novel therapeutic targets, and evaluate potential therapeutic strategies in a human-relevant context.
Topic: Human Liver Organoids Derived from Patients with Obesity: A Novel Platform for Disease Modeling and Drug Discovery